Intra- and inter-radiation therapist reproducibility of daily isocenter verification using prostatic fiducial markers
© Ullman et al; licensee BioMed Central Ltd. 2006
Received: 12 December 2005
Accepted: 28 February 2006
Published: 28 February 2006
We sought to determine the intra- and inter-radiation therapist reproducibility of a previously established matching technique for daily verification and correction of isocenter position relative to intraprostatic fiducial markers (FM).
Materials and methods
With the patient in the treatment position, anterior-posterior and left lateral electronic images are acquired on an amorphous silicon flat panel electronic portal imaging device. After each portal image is acquired, the therapist manually translates and aligns the fiducial markers in the image to the marker contours on the digitally reconstructed radiograph. The distances between the planned and actual isocenter location is displayed. In order to determine the reproducibility of this technique, four therapists repeated and recorded this operation two separate times on 20 previously acquired portal image datasets from two patients. The data were analyzed to obtain the mean variability in the distances measured between and within observers.
The mean and median intra-observer variability ranged from 0.4 to 0.7 mm and 0.3 to 0.6 mm respectively with a standard deviation of 0.4 to 1.0 mm. Inter-observer results were similar with a mean variability of 0.9 mm, a median of 0.6 mm, and a standard deviation of 0.7 mm. When using a 5 mm threshold, only 0.5% of treatments will undergo a table shift due to intra or inter-observer error, increasing to an error rate of 2.4% if this threshold were reduced to 3 mm.
We have found high reproducibility with a previously established method for daily verification and correction of isocenter position relative to prostatic fiducial markers using electronic portal imaging.
Carcinoma of the prostate is the most common form of cancer in men . In 2005, 232,090 new cases of prostate cancer and 30,350 prostate cancer deaths were projected in the United States . External beam radiotherapy constitutes one of the mainstays of therapy for patients with localized disease. Given the relatively small treatment fields used with conformal and intensity-modulated radiotherapy, there is a greater need for accurate targeting and daily localization of the prostate gland, a task is being performed by radiation therapists/technologists.
The prostate is located between the bladder and the rectum, and its position within the pelvis can change according to the degree of fullness of the bladder and rectum. Variations in bladder and rectal filling have been shown to affect prostate position within the pelvis, to an extent which may require field adjustments during the course of radiotherapy . Since the rectum tends to become progressively less distended during a course of pelvic radiotherapy (mean decrease in diameter 1.5 cm), the predominant prostate motion is in the posterior and inferior direction. In one study, 11% of patients showed an inferior shift of the prostate of more than 1 cm and 30% showed a posterior shift of more than 1 cm . Indeed, this variation in position cannot be assessed with external skin marks or bony landmarks, the standard approach used by radiation therapists on a daily basis. Any motion of the target relative to these landmarks limits the accuracy of radiotherapy. A safety margin is therefore applied during treatment planning to ensure correct irradiation of the target in spite of this movement.
Portal x-ray imaging is a technique used to monitor the accuracy of beam isocenter positioning relative to bony landmarks or fiducial markers during radiotherapy. Since the prostate is not visible on portal imaging, radiopaque fiducial markers are surrogates for organ localization in portal images . As prostate motion is the major source of error in radiation treatment delivery , some investigators have recommended that radio-opaque markers be placed in the prostate prior to the start of radiotherapy. In our clinic, a previously described technique for daily electronic portal imaging device (EPID) visualization and alignment to prostate fiducial markers has been implemented to reduce inter-fractional set-up uncertainty, with the eventual goal of safely reducing PTV margins and normal tissue dose . In order to determine, in part, the targeting error associated with this technique, we sought to measure intra and inter-radiation therapist variability using fiducial markers for daily set-up assessment and adjustment of external radiation beam targeting.
Methods and materials
Fiducial marker placement under MRI-guidance
The patient subjects of this study were enrolled on an IRB approved protocol after providing informed consent. The primary objective of this protocol was to validate the accuracy and tolerability of a new device that allows for the placement of needles and fiducial markers within the prostate gland based upon MR images instead of standard ultrasound images. The secondary objective was to gain experience using fiducial markers for daily assessment and adjustment of external radiation beam targeting as performed by radiation therapists.
Four sterile gold fiducial markers (1.2 × 3 mm, Med Tec® – NWMP, Iowa) are placed within the prostate under MRI guidance one week before external beam radiotherapy in patients with localized prostate cancer . Markers are placed at the prostate base, apex, and right and left margins at the level of the mid-gland. The patient returns four to five days later for a treatment planning MRI and a treatment planning non-contrast CT.
Treatment planning MRI consists of a T2-weighted fast spin echo (FSE) acquisition (3500/120 TR/TE) for anatomic and tumor delineation, and a proton density 3D True Fast Imaging with Steady State Precession imaging (CE-TrueFISP – 4.7/2.4 TR/TE) for optimal marker visualization. Both image sets are acquired in the same axial orientation with 26 slices (3 mm thickness) and a field of view of 20 × 20 cm. The images are then superimposed and a reference MR image is created by identifying the marker locations on the anatomic T2-weighted FSE images.
Non-contrast treatment planning CT images are acquired with 3 mm slice thickness and a field of view of 48 cm to encompass the skin surface. For both MRI and CT treatment planning image acquisitions, patients empty their bladders and are positioned supine with no knee support and their feet bound together. The reference MR images are then rigidly co-registered to the CT images (AcQSim, Philips Medical Systems, Netherlands) by identifying the common fiducial marker locations. The clinical target volume (CTV), which most commonly comprises the prostate gland, is defined on the co-registered reference MR image. The seminal vesicles, the rectum, and the streaking artifact from the fiducial markers are segmented on the CT images. Note that bloom artifact from the fiducial markers was similarly present on MR images.
A margin of 1.5 cm radial and 1 cm posterior is added to the CTV to generate the PTV for the first phase of the treatment. After 46Gy, the margin is reduced to 1 cm radial and 0.7 cm posterior, consistent with standard of care without daily image verification . The total dose delivered ranges from 70–74Gy. A treatment plan is generated with a four-field technique to encompass the PTV with the 98–100% isodose. The radiation dose is prescribed to the 100% isodose. Digitally reconstructed radiographs (DRRs) with the overlying MLC profile and fiducial marker outlines are generated, electronically saved, and printed for reference to the portal films acquired on the first day of treatment.
Daily verification and correction of isocenter position
Isocenter placement relative to fiducial markers is verified on a daily basis prior to radiation delivery using an EPID on the linear accelerator (Clinac ® 21EX-Varian). With the patient in the treatment position, anterior-posterior and left lateral electronic images are acquired with an amorphous silicon (a-Si) flat panel EPID. A single portal image exposure is acquired using the treatment field's MLC profile and energy. The fiducial markers are clearly visible using 5 and 7 monitor units (MU) for the AP and lateral portal images respectively. This portal imaging dose is included in the daily treatment dose delivery.
Study design- determination of intra and inter-therapist reproducibility
Datasets for 10 treatments (10 AP and 10 Left Lateral portal images) in each of two patients were archived for this study, for a total of 40 images. Radiation therapists familiar with the daily verification technique were instructed to manually align the fiducial markers and document the two absolute orthogonal shift distances for all 40 images, for a total of 80 measurements. Therapists were instructed to perform this task independently. This exercise was repeated, within one to two days, by each of the four therapists. Data were tabulated, and the intra and inter-radiation therapist variability was calculated with simple descriptive statistics, including the mean, median, and standard deviation of the data. The data were analyzed in terms of absolute difference between any pair of alignments. Inter-radiation therapist variability analysis was therefore based on 1920 data points, derived from 24 comparison datasets of 80 points each (6 comparisons for each of 4 radiation therapists).
A very small but statistically significant difference was found in observer variability between lateral and AP portal image manual matches (AP mean 0.8 mm [CI 0.75–0.84], LLAT mean 1 mm [CI 0.94–1.1], P < 0.01).
This technique has now been clinically applied in 166 consecutive treatments in 6 patients. For the first 83 treatments, with a repositioning threshold of 5 mm, 30 treatments required table shifts prior to radiation delivery (36%). For the latter 83 treatments, with a threshold of 3 mm, 25 fractions required table shifts (30%). Approximately 5–10 minutes were dedicated to this verification depending on the need to reposition the patient.
With the advent of IMRT and highly conformal radiotherapy, there is mounting incentive to improve daily set-up and targeting accuracy of the prostate gland. Strategies to date have focused on reducing inter-fractional set-up error, and include alternative immobilization techniques, daily portal verification of isocenter position relative to bony landmarks , trans-abdominal ultrasound-based verification of prostate position relative to CT treatment planning contours (B-mode Acquisition and Targeting System -BAT®) , daily CT scans on the treatment couch , cone-beam CT mounted on the treatment gantry , and daily portal verification of fiducial marker locations relative to isocenter position [6, 14, 15]
In this study, we investigated the inter and intra-radiation therapist reproducibility in fiducial marker alignment using the "manual match" technique herein described. To our knowledge, there are no prior studies addressing this question. A review of the literature found two papers addressing intra and/or inter-user variability with trans-abdominal ultrasound for daily prostate positioning (BAT®). In Langen et al. , inter-user variability of the BAT® system was investigated with eight users, including 4 radiation oncologists, 2 physicists, 1 urologist, and only 1 radiation therapist. A variability of greater than 2 mm was found in 50%, and greater than 4 mm in 25% of cases. Using the same system, Serago et al.  found inter-user variability to be greater than 3 mm in approximately 10% of measurements, and intra-user variability was greater then 3 mm in approximately 5% of cases depending on the orientation of shift. Limitations of the BAT® system which may account for it's poor inter and intra-user reproducibility include error in the initial CT and isocenter definition of the BAT® test phantom, and uncertainties in the CT definition of the prostate which translate directly into a systematic uncertainty in the BAT® alignment .
Using the fiducial marker technique, we achieved superior results with an observer variability of greater than 3 mm observed in only 2.4% of cases. Furthermore, this was found with four radiation therapists involved in the routine treatment of our patients. Another advantage of the fiducial marker approach is that it is not dependent on the location of the prostate gland relative to the pubic symphysis  and is less dependent on patient size and weight . The variability we observed may in part be due to uncertainty in the manual alignment as the marker outline is larger than the radiopaque marker visualized on the portal image. Prior studies have shown that the markers do not migrate significantly during a course of therapy, and as such, are reliable surrogates to the position of the prostate gland [18, 19]. The technique does not require specialized localization software or hardware modifications beyond standard portal image software. It permits portal imaging to be limited to the treatment field for daily localization, sparing surrounding normal tissues from cumulative dose which would be delivered in alternative open field localization systems .
We have also found a very small (0.2 mm) but statistically significant increase in variability with the lateral alignment compared to the AP alignment. Although this difference is not clinically significant and is smaller than the pixel size of the EPID (0.8 mm), it may point to poorer visualization of the fiducial markers on the lateral image, or to greater difficulty in alignment due to rotation of the prostate gland along this axis.
There are limitations of our study design. We did not address the radiation therapist's accuracy in the actual table shift at the second verification. There was also no systematic assessment of time cost to this procedure on a daily basis. Finally, the four radiation therapists had a relatively short interval of one to two days between the two measurements. A larger user error might have been found by increasing this interval.
Despite our reported level of accuracy, we acknowledge that intra- and inter-radiation therapist variability is not the sole source of set-up error in this technique. For simplicity, we have opted to ignore rotational errors in alignment at the inception of this trial. Others have introduced a collimator rotation in the lateral treatment fields if the required rotation angle exceeds 3 degrees . Future work will determine the need, feasibility and reproducibility of such a correction, as well as an assessment of the important impact of intra-fractional organ and patient motion. This work will be necessary in order to determine whether PTV margins can be safely reduced with this technique.
In conclusion, we have found high intra and inter-radiation therapist reproducibility with a simple method for daily verification and correction of isocenter position relative to fiducial markers using electronic portal imaging. We believe this is an important first step toward an eventual goal of PTV reduction and safe dose escalation.
- Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 2005, 55: 10-30.View ArticlePubMedGoogle Scholar
- Ten Haken RK, Forman JD, Heimburger DK, Gerhardsson A, McShan DL, Perez-Tamayo C, Schoeppel SL, Lichter AS: Treatment planning issues related to prostate movement in response to differential filling of the rectum and bladder. Int J Radiat Oncol Biol Phys 1991, 20: 1317-1324.View ArticlePubMedGoogle Scholar
- Crook JM, Raymond Y, Salhani D, Yang H, Esche B: Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 1995, 37: 35-42. 10.1016/0167-8140(95)01613-LView ArticlePubMedGoogle Scholar
- Pang G, Beachey DJ, O'Brien PF, Rowlands JA: Imaging of 1.0-mm-diameter radiopaque markers with megavoltage X-rays: an improved online imaging system. Int J Radiat Oncol Biol Phys 2002, 52: 532-537. 10.1016/S0360-3016(01)02709-2View ArticlePubMedGoogle Scholar
- Wu J, Haycocks T, Alasti H, Ottewell G, Middlemiss N, Abdolell M, Warde P, Toi A, Catton C: Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiother Oncol 2001, 61: 127-133. 10.1016/S0167-8140(01)00452-2View ArticlePubMedGoogle Scholar
- Herman MG, Pisansky TM, Kruse JJ, Prisciandaro JI, Davis BJ, King BF: Technical aspects of daily online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal imaging device. Int J Radiat Oncol Biol Phys 2003, 57: 1131-1140. 10.1016/S0360-3016(03)00766-1View ArticlePubMedGoogle Scholar
- Krieger A, Susil RC, Menard C, Coleman JA, Fichtinger G, Atalar E, Whitcomb LL: Design of a novel MRI compatible manipulator for image guided prostate interventions. IEEE Trans Biomed Eng 2005, 52: 306-313. 10.1109/TBME.2004.840497PubMed CentralView ArticlePubMedGoogle Scholar
- Michalski JM, Purdy JA, Winter K, Roach M, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD: Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000, 46: 391-402. 10.1016/S0360-3016(99)00443-5View ArticlePubMedGoogle Scholar
- Malone S, Crook JM, Kendal WS, Szanto J: Respiratory-induced prostate motion: quantification and characterization. Int J Radiat Oncol Biol Phys 2000, 48: 105-109. 10.1016/S0360-3016(00)00603-9View ArticlePubMedGoogle Scholar
- Hatherly K, Smylie J, Rodger A: A comparison of field-only electronic portal imaging hard copies with double exposure port films in radiation therapy treatment setup confirmation to determine its clinical application in a radiotherapy center. Int J Radiat Oncol Biol Phys 1999, 45: 791-796. 10.1016/S0360-3016(99)00249-7View ArticlePubMedGoogle Scholar
- Serago CF, Chungbin SJ, Buskirk SJ, Ezzell GA, Collie AC, Vora SA: Initial experience with ultrasound localization for positioning prostate cancer patients for external beam radiotherapy. Int J Radiat Oncol Biol Phys 2002, 53: 1130-1138. 10.1016/S0360-3016(02)02826-2View ArticlePubMedGoogle Scholar
- Court LE, Dong L, Taylor N, Ballo M, Kitamura K, Lee AK, O'Daniel J, White RA, Cheung R, Kuban D: Evaluation of a contour-alignment technique for CT-guided prostate radiotherapy: an intra- and interobserver study. Int J Radiat Oncol Biol Phys 2004, 59: 412-418. 10.1016/j.ijrobp.2003.10.023View ArticlePubMedGoogle Scholar
- Jaffray DA, Siewerdsen JH, Wong JW, Martinez AA: Flat-panel cone-beam computed tomography for image-guided radiation therapy. Int J Radiat Oncol Biol Phys 2002, 53: 1337-1349. 10.1016/S0360-3016(02)02884-5View ArticlePubMedGoogle Scholar
- Alasti H, Petric MP, Catton CN, Warde PR: Portal imaging for evaluation of daily on-line setup errors and off-line organ motion during conformal irradiation of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 49: 869-884. 10.1016/S0360-3016(00)01446-2View ArticlePubMedGoogle Scholar
- Chung PW, Haycocks T, Brown T, Cambridge Z, Kelly V, Alasti H, Jaffray DA, Catton CN: On-line aSi portal imaging of implanted fiducial markers for the reduction of interfraction error during conformal radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 2004, 60: 329-334. 10.1016/j.ijrobp.2004.03.038View ArticlePubMedGoogle Scholar
- Langen KM, Pouliot J, Anezinos C, Aubin M, Gottschalk AR, Hsu IC, Lowther D, Liu YM, Shinohara K, Verhey LJ, Weinberg V, Roach M: Evaluation of ultrasound-based prostate localization for image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2003, 57: 635-644. 10.1016/S0360-3016(03)00633-3View ArticlePubMedGoogle Scholar
- Millender LE, Aubin M, Pouliot J, Shinohara K, Roach M: Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 59: 6-10. 10.1016/j.ijrobp.2003.12.027View ArticlePubMedGoogle Scholar
- Poggi MM, Gant DA, Sewchand W, Warlick WB: Marker seed migration in prostate localization. Int J Radiat Oncol Biol Phys 2003, 56: 1248-1251. 10.1016/S0360-3016(03)00328-6View ArticlePubMedGoogle Scholar
- Pouliot J, Aubin M, Langen KM, Liu YM, Pickett B, Shinohara K, Roach M: (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. Int J Radiat Oncol Biol Phys 2003, 56: 862-866. 10.1016/S0360-3016(03)00267-0View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.